PT - JOURNAL ARTICLE AU - Hrybouski, Stanislau AU - Das, Sandhitsu R. AU - Xie, Long AU - Brown, Christopher A. AU - Flamporis, Melissa AU - Lane, Jacqueline AU - Nasrallah, Ilya M. AU - Detre, John A. AU - Yushkevich, Paul A. AU - Wolk, David A. TI - BOLD Amplitude Correlates of Preclinical Alzheimer’s Disease AID - 10.1101/2024.10.27.24316243 DP - 2024 Jan 01 TA - medRxiv PG - 2024.10.27.24316243 4099 - http://medrxiv.org/content/early/2024/10/29/2024.10.27.24316243.short 4100 - http://medrxiv.org/content/early/2024/10/29/2024.10.27.24316243.full AB - Alzheimer's disease (AD) is characterized by a long preclinical stage during which molecular markers of amyloid beta and tau pathology rise, but there is minimal neurodegeneration or cognitive decline. Previous literature suggests that measures of brain function might be more sensitive to neuropathologic burden during the preclinical stage of AD than conventional measures of macrostructure, such as cortical thickness. However, among studies that used resting-state functional Magnetic Resonance Imaging (fMRI) acquisitions with Blood Oxygenation Level Dependent (BOLD) contrast, most employed connectivity-based analytic approaches, which discard information about the amplitude of spontaneous brain activity. Consequently, little is known about the effects of amyloid and tau pathology on BOLD amplitude. To address this knowledge gap, we characterized the effects of preclinical and prodromal AD on the amplitude of low-frequency fluctuations (ALFF) of the BOLD signal both at the whole-brain level and, at a more granular level, focused on subregions of the medial temporal lobe. We observed reduced ALFF in both preclinical and prodromal AD. In preclinical AD, amyloid positivity was associated with a spatially diffuse ALFF reduction in the frontal, medial parietal, and lateral temporal association cortices, while tau pathology was negatively associated with ALFF in the entorhinal cortex. These ALFF effects were observed in the absence of observable macrostructural changes in preclinical AD and remained after adjusting for structural atrophy in prodromal AD, indicating that ALFF offers additional sensitivity to early disease processes beyond what is provided by traditional structural imaging biomarkers of neurodegeneration. We conclude that ALFF may be a promising imaging-based biomarker for assessing the effects of amyloid-clearing immunotherapies in preclinical AD.Competing Interest StatementAvid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Eli Lilly and Company, enabled the use of the 18F-flortaucipir tracer by providing precursor, but did not provide direct funding and was not involved in data analysis or interpretation. D.A.W. has served as a paid consultant to Eli Lilly, GE Healthcare and Qynapse. He serves on a DSMB for Functional Neuromodulation. He receives research support paid to his institution from Biogen. I.M.N. has served on a Scientific Advisory Board for Eisai, has done educational speaking for Peerview, and has been a consultant for Subtle Medical. He serves on a DSMB for a drug trial for obstructive sleep apnea. L.X. received personal consulting fees from Galileo CDS, Inc. L.X. has become an employee of Siemens Healthineers since May 2022 but the current study was conducted during his employment at the University of Pennsylvania. All other authors report no competing interests.Funding StatementThe work in the present study was supported by the Alzheimer's Association (Grant AARF-21- 48972), Fred A. and Barbara M. Erb Foundation/Alzheimer's Association (Grant AACSF-23-1152241), and by the National Institutes of Health (Grants P30-AG072979, R01-AG069474, RF1-AG056014, R01-AG055005, R01-AG072796, R25-NS065745, and R01-AG070592).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Pennsylvania Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAnonymized pre-processed data and in-house analysis scripts will be made available upon request for the sole purpose of replicating procedures and results presented in this article.